Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor
Cancer Science - United States
doi 10.1111/cas.13536
Full Text
Open PDFAbstract
Available in full text
Date
March 25, 2018
Authors
Publisher
Wiley